KYTX (Kyverna Therapeutics) Research & Development: $126.36 Mil (TTM As of Mar. 2026)


KYTX Kyverna Therapeutics Inc KYTX
12 GF Score
Price $8.44
! 1 Warning Sign
View Full Analysis

What is Kyverna Therapeutics Research & Development?

Kyverna Therapeutics KYTX +2.93% 12 Research & Development is $126.36 Mil as of Mar. 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Kyverna Therapeutics's Research & Development for the three months ended in Mar. 2026 was $30.07 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $126.36 Mil.

Kyverna Therapeutics  (NAS:KYTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kyverna Therapeutics Research & Development Related Terms

Kyverna Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Kyverna Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics Research & Development Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
25.85 28.40 49.92 112.47 133.72

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.43 35.82 30.46 30.01 30.07
KYTX
12GF Score
Kyverna Therapeutics Inc KYTX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyverna Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $126.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $126.36 Mil mean?
Kyverna Therapeutics (KYTX) has a Research & Development of $126.36 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Kyverna Therapeutics and its competitors.
Is Kyverna Therapeutics' Research & Development too high?
Kyverna Therapeutics' current Research & Development is $126.36 Mil. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' Research & Development compare to FDMT and XOMA?
Kyverna Therapeutics' Research & Development of $126.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current Research & Development is $126.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current Research & Development of $126.36 Mil. The current Research & Development is $126.36 Mil. Kyverna Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current Research & Development is $126.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kyverna Therapeutics Business Description

Address 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score

Get the complete analysis for KYTX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.44
Price